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Objectives: Fetal mutations and fetal chromosomal abnormalities can be detected by molecular analysis
of circulating cell free fetal DNA (ccffDNA) from maternal plasma. This comprehensive study was aimed to
investigate and verify blood collection and blood shipping conditions that enable Noninvasive Prenatal Test-
ing. Speciﬁcally, the impact of shipping and storage on the stability and concentration of circulating cell-free
DNA (ccfDNA) in Streck® Cell-Free DNA™ Blood Collection Tubes (Streck BCTs, Streck, Omaha NE). These
BCTs were designed to minimize cellular degradation, and thus effectively prevent dilution of fetal ccf DNA
by maternal genomic DNA, was evaluated.
Design and methods: Peripheral venous maternal blood was collected into Streck BCTs to investigate
four aspects of handling and processing conditions: (1) time from blood draw to plasma processing; (2) storage
temperature; (3) mechanical stress; and (4) lot-to-lot tube variations.
Results:Maternal blood stored in Streck BCTs for up to 7 days at ambient temperature provides stable con-
centrations of ccffDNA. The amount of fetal DNA did not change over a broad range of storage temperatures
(4 °C, 23 °C, 37 °C, 40 °C), but the amount of total (largely maternal) DNA increased in samples stored at
23 °C and above, indicating maternal cell degradation and genomic DNA release at elevated temperatures. Ship-
ping maternal blood in Streck BCTs, did not affect sample quality.
Conclusions: Maternal plasma DNA stabilized for 0 to 7 days in Streck BCTs can be used for non-invasive
prenatal molecular applications, when temperatures are maintained within the broad parameters assessed in
this study.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Chromosomal, genetic and biochemical abnormalities of the fetus
are routinely detected by analyzing fetal cells obtained through invasive
procedures such as amniocentesis and chorionic villus sampling [1]. A
small but deﬁnite risk of injury to both mother and fetus is imparted
by invasive sampling procedures [2]. An alternate source of geneticirculating cell-free fetal DNA;
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Inc. Open access under CC BY-NC-NDmaterial that accurately represents fetal status is circulating cell-free
fetal DNA (ccffDNA) found in maternal plasma. The placenta is thought
to be themain source for ccffDNA, and consequent clearance of ccffDNA
frommaternal plasma occurswithin hours after birth [3,4]. Recently the
use of ccffDNA has enabled the introduction of non-invasive prenatal
testing (NIPT) methods such as fetal RHD genotyping from maternal
plasma [5] and fetal aneuploidy detection in high risk women [6]. How-
ever, care must be taken to prevent an increase of circulating maternal
DNA after phlebotomy (through maternal white cell lysis), because
quantitative applications, such as non-invasive aneuploidy detection,
are impaired by a relative decrease in fetal fraction (FF). Typical fetal
fractions range from 2% to 40% with a mean of 10% of total ccfDNA
across varying gestational ages [6,10]. The minimum fetal fraction for
accurate determination of Trisomy 21 is 4% as measured by the Fetal
Quantiﬁer Assay (FQA) and set as QC cut-off [6]. Thus a small increase
in maternal DNA could reduce the fetal fraction below the 4% QC cut
off, particularly in cases of low initial fetal fraction. Below 4% FF no
test results would be reported. Enabling the access of a broad popula-
tion of mothers to non-invasive prenatal testing methods requires ro-
bust and validated blood collection devices and processing protocols. license.
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collected into standard EDTA Tubes require cold storage of the blood
samples followed by plasma preparation within 6 h. Plasma prepara-
tion initiates with a low speed centrifugation of maternal blood for
fractionation of the plasma from blood cells. The plasma layer is subse-
quently removed and centrifuged at a higher speed to pellet any resid-
ual debris from the plasma. Plasma processing is cumbersome and thus
only performed at collection sites when absolutely necessary due to lo-
cation or other circumstances. The requirement for immediate process-
ing to plasma for blood collected in standard EDTA Tubes, and the
associated costs of processing at collection sites, would unnecessarily
limit the availability of NIPT to a broad population. To overcome these
challenges, an ideal blood collection device would enable shipment of
whole blood at ambient temperatures (6 °C–37 °C) and extend the
timeframe for plasma processing. Such a devicewould facilitate central-
ized processing and analysis. Several alternatives to EDTA Tubes exist
for collecting blood and preparing plasma for molecular diagnostic
tests. Three potential tube types for maintaining fetal fractions can be
found: tubes that are designed to create a physical barrier (gel plug or
mechanical separator) between cellular and non-cellular blood compo-
nents, tubes providing reagents for keeping maternal blood cells intact
and active for a deﬁned period of time, and tubes with cell-preserving
reagents. A tube with cell-preserving reagents to prevent white blood
cell degradation (which would release maternal DNA) and inhibit
nuclease mediated DNA degradation for up to 14 days at ambient tem-
perature was recently introduced by Streck and marketed as Streck
Cell-Free DNA™ BCT (Streck BCTs)[7].
Barrett and colleagues revealed that the concentrations of
“short-fragment” ccffDNA from blood collected Streck BCTs did not
change when stored at ambient temperature over a period of 72 h.
However, when blood was stored in EDTA Tubes for 72 h, an increase
in “long-fragment” (maternal) plasma DNA was evident [8]. Results
by Hidestrand et al. indicated that in blood collected into EDTA
Tubes that were shipped either with or without frozen ice packs
had an increased level of total plasma DNA after 72 h. When whole
blood in Streck BCTs is shipped without ice packs (72 h) the level of
total DNA is unchanged, while when shipped with frozen ice packs,
the level of total DNA is reported to increase [9].
This study was aimed to characterize the ability of the Streck BCTs
to maintain ccff DNA concentrations and inhibit nuclease mediated
DNA degradation under conditions that are pragmatic for routine
use for clinical applications. Our evaluation of the utility of the Streck
BCT to preserve the integrity of the fetal DNA fraction focused on four
key variables: inﬂuence of storage time (up to 14 days), storage tem-
perature (for 24 h of storage), mechanical stress (ASTM Standard
D5276-98) and lot-to-lot consistency (3 lots).Materials, methods and experimental
Blood samples
Blood collection protocols
Patients were selected based on the following inclusion criteria:
1) Subject must be pregnant carrying a singleton fetus of 10–16 weeks
of gestational age inclusive. 2) Subject must be 18 years of age or older
or an emancipated minor. 3) Subject has consented to have up to
50 mL of whole blood collected at one or more monthly (≥25 days)
scheduled clinic visits.
Blood from patients, up to 5 × 10 mL of peripheral blood, was col-
lected by venipuncture in varying combinations of two types of evac-
uated blood collection tubes, Vacutainers® — K2EDTA Tubes (BD #
366643, referred to as EDTA Tubes in text; Becton, Dickinson and
Company Franklin Lakes, NJ) and Cell-Free DNA Streck™ BCT (Streck
# 218962, referred to as Streck BCTs in text; Streck Omaha, NE).
Streck BCTs contain K3EDTA as anticoagulant.EDTA Tubes
Blood collected in K2EDTA Tubes was transported chilled, with re-
frigerated ice packs, to a processing center and plasma was isolated
within 6 h of blood draw unless otherwise indicated. The ﬁrst centrifu-
gation was conducted at 2500 ×g for 10 min at 4 °C, after which the
plasma was carefully removed and transferred to a fresh tube. The sec-
ond centrifugation was conducted at 15,500×g for 10 min at 4 °C. The
resultant plasma was collected and stored frozen at ≤−70 °C until
analysis.
Streck BCTs
Blood collected in Streck BCTs was shipped at ambient tempera-
ture to a processing center and plasma was isolated within 24 h of
blood draw, unless otherwise indicated. The ﬁrst centrifugation was
at 1600 ×g for 15 min at room temperature, after which the plasma
was carefully removed and transferred to a fresh tube. The second
centrifugation was at 2500×g for 10 min at room temperature. The
resultant plasma was collected and stored frozen at ≤−70 °C until
analysis.
DNA extraction
EDTA and Streck BCT plasma samples were thawed and
centrifuged at 1600 ×g for 10 min at 4 °C. Four mL of the supernatant
was removed and circulating DNA was extracted with the QIAamp®
DSP Circulating NA Kit (QIAGEN Cat# 61504, Hilden, Germany). The
manufacturer's protocol was followed for EDTA plasma; Streck plas-
ma extraction utilized an extended Proteinase K digestion time of
60 min. DNA was eluted with 55 μL of Qiagen Buffer AVE (elution
buffer) from the QIAamp kit.
DNA quantitation
Fetal and total circulating DNA was detected using the FQA, a
methylation-sensitive, single nucleotide extension MALDI-TOF MS
assay [10]. This assay is capable of determining the gender of the
fetus, and of quantifying fetal DNA (regardless of gender). FQA was
run as indicated with 10 or 12.5 μL of extracted circulating DNA in
quadruplicate PCR and quadruplicate MS reactions (16 reactions
total). Data were analyzed as described [10]; total and fetal copies
per mL plasma are provided by dedicated scripts, from which the
fetal fraction was calculated. For total copies the dynamic range of
the FQA assay is between 450 and 7500 [10]. Samples with total
DNA copy numbers that were above the maximum dynamic range
of the assay were adjusted to 7500 copies before normalization.
Study variables
Storage time
Blood was stored in EDTA Tubes and in Streck BCTs for 1 to 14 days
and compared to EDTAor Streck no-storage-control (NSC), respectively.
From each donor (20 pregnant female, 10 non-pregnant female, or 10
male subjects per time point, respectively) blood was collected into 2
EDTA Tubes and 2 Streck BCTs (10 mL per tube). EDTA NSC and Streck
NSC were generated by processing blood into plasma within 6 h post
blood draw. Blood in remaining EDTA Tubes and Streck BCTswas stored
for either 1 day, 2 days, 3 days, 4 days, 7 days, or 14 days, after which
plasma was prepared and stored frozen at ≤−70 °C until use.
Before extracting ccfDNA, all plasma samples were thawed and
centrifuged at 1600 ×g for 10 min to pellet debris. FQA reactions
were performed in quadruplicate using 10 μL of extracted DNA [10].
Data were analyzed using either: i) ANOVA for EDTA and Streck NSC
for Day 1 to Day 14, and ii) comparing EDTA NSC of a speciﬁc subject
(e.g. Subject 1 of Day 1) to the matched samples stored in EDTA Tubes
and Streck BCTs.
Fig. 1. Circulating DNA recovery from pregnant female blood stored for 0–14 days in
control EDTA and cell preservation tubes. Results from 20 subjects per time point
(Streck BCTs (red) and EDTA BCTs (black)) were normalized to their respective no
storage controls. A. Fetal DNA, B. Total DNA and C. Fetal Fraction. Medians are
connected by lines (red: Streck BCTs, black: EDTA Tubes). Statistically signiﬁcant differ-
ences (p-value b0.05) between EDTA and Streck BCTs are indicated with an “*”.
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controls were calculated and used to normalize the values for Day 1,
Day 2, Day 3, Day 4, Day 7 and Day 14 samples. To facilitate the
comparison between the blocked time points, normalization was
performed on the raw data. Normalization caused the resulting max-
imum values for total DNA copies on Days 7 and 14 total DNA to rise
above 7500.
Constant temperature stress
Five aliquots of 10 mL of peripheral blood obtained from each of
20 pregnant females were drawn into separate Streck BCTs. One
tube from each subject was processed into plasma within 30 h of
blood draw (tube 1: NSC); the remaining 4 tubes were stored for
24 h at 4 °C, 23 °C (room temperature), 37 °C, and at 40 °C. After
24 h of incubation, blood was processed into plasma and frozen. For
each subject a paired t-test was employed to compare each tempera-
ture point to the respective NSC.
Lot-to-lot consistency
Three different lots of Streck BCTs were tested in a paired set-up.
Each lot was manufactured in separate production batches (different
days). Two of the 3 lots were manufactured within a month of each
other with the third manufactured 7 months earlier (based on expi-
ration dates). Blood from each of 49 pregnant females was drawn
into Streck BCTs lots 1, 2 and 3, resulting in 2 tubes of lot 1, 2 tubes
of lot 2 and 1 tube of lot 3. ANOVA was applied. In addition the me-
dians of each condition were analyzed using a paired t-test.
Massively parallel sequencing (MPS) library preparation
Blood from 22 subjects was collected into 2 EDTA Tubes and 2
Streck BCTs each. EDTA plasma was prepared within 6 h of blood
draw, while Streck plasma was prepared after blood was stored for
three days at room temperature. Circulating DNA was isolated and
an aliquot was used in the Fetal Quantiﬁer Assay for the evaluation
of fetal fraction as an assessment of quality. Sequencing libraries
were prepared according to a standard protocol [6]. Library concen-
trations were determined using a Caliper LabChip GX electrophoresis
apparatus (Caliper BioSciences).
Statistical analysis
The R statistical programming environment was used to perform
statistical analyses [11]. Additional analysis was performed using
JMP 9 (Version 9.0.1, SAS).
Power analysis
Using results from previous paired studies, a power analysis in
JMP was performed. Applying a power of 80%, α = 0.05 on a sample
size of 20, for fetal copy number and for fetal fraction (fetal copies/
total copies per mL plasma), a 35% difference can be discerned; for
total DNA copies the value drops to 30%. In the study comparing dif-
ferent production lots of Streck BCTs, the sample size was increased
to 49 subjects, ensuring that potential differences in fetal copies of
22% can be reliably detected, 19% for total DNA copies and 21% for
the fetal fraction.
Patients
Blood samples were collected under two separate Institutional Re-
view Board (IRB) approved protocols, to ensure that enough samples
were collected in the twoweek timeframe planned for the completion of
blood collection for this study (both with Compass IRB). Informed con-
sent was obtained from pregnant females, conﬁrmed non-pregnant
females, and males prior to collection of up to 5 × 10 mL of peripheral
blood by venipuncture.Results
After an initial screen of blood collection tubes for extended blood
storage, including tubes with plugs, and with cell maintenance or cell
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further studies.
Analysis of 240 Streck plasma samples from individual pregnant
women identiﬁed 42% female fetuses (n = 101) and 58% male fe-
tuses (n = 139). Of the 240 pregnant females, gestational age was
available in 218. The mean (median) gestational age was 14.73
(13.40) weeks, with a minimum of 10 and a maximum of 27 weeks.
The range of the collected ccfDNA spanned 2% to 62%, 38–949 fetal
copies/mL, and 154 to 7500 total copies/mL.
Effect of storage time on pregnant female whole blood in cell
preservation tubes
The stability of ccfDNA in Streck BCTs was evaluated by comparing
to standard EDTA Tubes. Four aliquots were analyzed for each time
point: 2 aliquots, one in Streck BCT and one in EDTA Tubes were
processed to plasma directly after blood collection. Two additional
aliquots, again one in Streck BCT and one in EDTA Tubes, were
processed after a predeﬁned storage time. Using whole blood collected
from 20 different pregnant women, six storage time points were evalu-
ated, each with a corresponding no storage (Day 0) control. Total and
fetal copy numbers were assessed by FQA and the raw data is shown
in Supplemental Data Fig. 3. To enable a direct comparison between
storage times (Day 1 to Day 14), a normalization schema was applied
using the median of the no storage controls as a reference. A more de-
tailed description of the normalization methods is provided in the
Supplemental Data. The normalized data and analysis is presented in
Fig. 1 and Table 1, along with the Day 0 control reference.
Whole blood collected and stored in EDTA Tubes prior to process-
ing plasma demonstrates a statistically signiﬁcant increase in total
DNA copy numbers after only one day of ambient temperature stor-
age. In EDTA Tubes, the increase in total copy number continued
throughout 14 days of storage. By Day 2, an increasing amount of
samples was measured outside the linear range for quantiﬁcation
(7500 copies). The EDTA median total copy numbers were 1454 for
Day 1, 2631 for Day 2, 7494 for Day 3, 7207 for Day 4, 7590 for Day
7 and 7995 for Day14 (black line, Fig. 1A and Table 1). For blood col-
lected in Streck BCTs the results are remarkably different. In Streck
BCTs, at up to 7 days storage of whole blood, total copy numbers
were not different from the immediately processed samples
(p > 0.06, paired t-test, see Table 1). In Streck BCTs, at 14 days a sta-
tistically signiﬁcant increase in total DNA copy numbers was ob-
served (median = 2443, p b 0.001 at Day 14; red line, Fig. 1B).
Fetal copies were stable over 14 days for both EDTA and Streck
plasma with one exception. The samples stored in EDTA for 14 days
also showed an increase in fetal copy numbers (black line, Fig. 1A).Table 1
Median total, fetal copy numbers and fetal fraction in plasma from 20 pregnant females pe
Median for pregnant female samples
Fetal copies/mL Total copies/mL Fetal fraction
Streck BCTs
Day 1 223 1085 0.187
Day 2 221 1257 0.177
Day 3 256 1328 0.209
Day 4 257 1398 0.177
Day 7 241 1370 0.184
Day 14 255 2443 0.128
EDTA Tubes
Day 1 263 1454 0.164
Day 2 254 2631 0.098
Day 3 246 7494 0.038
Day 4 246 7207 0.036
Day 7 244 7590 0.032
Day 14 721 7995 0.105This effect is most likely attributed to the extremely high total copy
numbers, which led to incomplete digestion during the methylation
sensitive restriction digest step in the assay (FQA).
Fetal fraction is calculated as the quotient of fetal copy numbers
and total copy numbers. In this storage time study the fetal copy
numbers remained mostly stable and consequently the fetal fraction
is largely a reﬂection of the changes in total copy numbers. No statis-
tically signiﬁcant differences (p > 0.163, paired t-test) were observed
for samples collected in Streck BCTs up to and including Day 7, while
samples stored in EDTA Tubes demonstrated a signiﬁcant decrease
starting at Day 2 (Fig. 1C, Table 1).Effect of storage time on non-pregnant female and male whole blood in
cell preservation tubes
Results observed in samples from pregnant females were conﬁrmed
in non-pregnant female and male subjects. Analogous to the previous
study, 10 subjects were enrolled per time point. The data do not
show a statistically signiﬁcant increase (p > 0.071) in total copy num-
bers for samples collected in Streck BCTs; however, starting on Day 2,
total DNA is increased for samples stored in EDTA (Supplemental Data
Figs. 4 and 5).Effect of four different storage temperatures on pregnant female blood
Blood collected and shipped in Streck BCTs was stored at four tem-
peratures. One tube each from 20 pregnant females was processed
into plasma after it was received from the blood collection sites, usu-
ally within 30 h after blood draw (reference control sample). The
remaining four blood tubes were stored for 24 h at 4 °C, 23 °C,
37 °C and 40 °C.
A paired t-test was employed to compare each temperature point
to the reference control sample. Total DNA copies increased slightly
after storage at 4 °C (median = 1174, p = 0.343), but a statistically
signiﬁcant effect was observed after storage at 23 °C (median =
1394, b0.001; Fig. 2B). A further increase in total copies was evident
after storage at 37 °C (median = 1882, p b 0.001) and 40 °C
(median = 1950, p b 0.001), leading to a continuous drop in fetal
fraction. Fetal copy numbers at 4 °C, 23 °C, 37 °C and 40 °C were sim-
ilar to the control (overall median = 166, Fig. 2A). Paired t-test re-
sults further revealed that the fetal fraction for samples stored at
23 °C (median = 0.115, p b 0.001) and the 37 °C (median = 0.08,
p b 0.001, Fig. 2C) samples was signiﬁcantly lower than the control
samples.r time point, stored for 1 to 14 days in Streck BCTs and EDTA Tubes.
p-values for paired t-test*
Fetal copies/mL Total copies/mL Fetal fraction
Day 1 0.6537 0.686 0.1626
Day 2 0.5493 0.2628 0.2213
Day 3 0.9792 0.5333 0.8861
Day 4 0.3443 0.1165 0.4333
Day 7 0.8853 0.0612 0.3828
Day 14 0.5078 0.0001* 0.0050*
Day 1 0.9681 0.1487 0.0682
Day 2 0.9845 0.0007* b0.0001*
Day 3 0.8693 b0.0001* b0.0001*
Day 4 0.7667 b0.0001* 0.0261*
Day 7 0.7401 b0.0001* b0.0001*
Day 14 0.0142* b0.0001* 0.9806
Fig. 2. Recovery of circulating DNA from pregnant female blood stored in cell preserva-
tion tubes 4 °C, 23 °C, 37 °C or at 40 °C. Blood stored in Streck BCTs for 24 h at the in-
dicated temperatures before DNA extraction. A. Fetal DNA, B. Total DNA and C. Fetal
Fraction. NS: no storage. Statistically signiﬁcant differences (p-value b0.05) between
EDTA and Streck BCTs are indicated with an “*”.
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To further investigate impact of shipping conditions and poten-
tially rough handling on whole blood, a drop test according to
ASTM Standard was employed. In this study, blood tubes were pack-
aged with considerations to International Air Transport Association(IATA) and International Civil Aviation Organization (ICAO) regula-
tions for the safe transport of Biological Substances, Category B
(UN3373). Two tubes from each of 20 patients collected in Streck
BCTs were packaged into an absorbent protective sleeve along with
3 additional Streck BCTs ﬁlled with water, to simulate a shipment.
The tubes in sleeves were rolled up and placed into a standard bio-
hazard bag. The bag was placed between insulating gel packages in
9 in. by 7 in. by 4.5 in. shipping box, which was sealed and dropped
from exactly 3 ft above the ﬂoor. The two remaining non-drop ali-
quots from each patient served as controls. All dropped and control
samples were unpacked and analyzed according to the standard pro-
tocol. This test was repeatedwith a fresh set of material (sleeves, bio-
hazard bag, additional water ﬁlled Streck BCTs and shipping box) for
each of the 20 patients used for this study. Based on a paired t-test,
no statistically signiﬁcant differences (p > 0.181) between dropped
and control samples were observed for total or fetal DNA as well as
fetal DNA percentage (Supplemental Data Fig. 7).
Cell preservation tube lot-to-lot consistency
In a paired set-up reproducibility in recovering circulating fetal DNA
was compared in three production lots of Streck BCTs (Supplemental
Data Fig. 8). ANOVA (p = 0.1685 for total copies, p = 0.9080 for fetal
copies, p = 0.1436 for fetal fraction) showed no statistically signiﬁcant
differences between the three lots. A paired t-test showed a small but
statistically signiﬁcant difference in total circulating plasma DNA be-
tween lot 1 and lot 2 or lot 3 (Supplemental Data Table 3).
Massively parallel sequencing (MPS) library preparation with ccfDNA
Streck BCTs contain 200 μL of a proprietary preserving reagent. Previ-
ous studies have indicated that this reagent does not interfere with real
time PCR results. EDTA and Streck ccfDNA was compared in a second
downstream application, the library preparation for non-invasive prena-
tal aneuploidy detection by MPS. No signiﬁcant difference in the DNA
concentration of sequencing libraries was detected (EDTA mean =
171 nM and Streck mean = 164 nM, p = 0.524; Supplemental Data
Fig. 9).
Discussion
This comprehensive study evaluates the operating range for a
blood collection tube with cell stabilizing agents reported to prevent
cell degradation. The stability of maternal blood collected in Streck
BCTs for up to 14 days at ambient temperature was tested. For
whole blood collected in Streck BCTs and stored at ambient tempera-
tures over a period of 14 days, the concentration of fetal DNA did not
signiﬁcantly change. An increase in total DNA is noted only at Day 14
and this is likely caused by white blood cell degradation. The shipping
and storage temperature has a larger than expected effect on cell in-
tegrity, with a strong temperature effect observed at 37 °C and 40 °C.
Overall, when compared to standard EDTA Tubes the Streck BCTs
show a clear effect of stabilizing cell integrity and fetal fraction and
can thus enable a simpliﬁed sample collection process.
Currently the two main applications for plasma ccfDNA include
cancer and prenatal diagnoses. The majority of these tests are run in
centralized facilities similar to a core lab of a major hospital. Given
the excellent shipping infrastructure in the United States it is safe to
assume that samples can be transferred from the time of blood collec-
tion to the testing facility within 3 days throughout the continent
using commercial carriers. The data presented in this study indicate
that cell integrity is preserved for up to seven days. Besides shipping
or storage times affecting the integrity of maternal cells, shipping
temperature or physical shock might also be negative effectors. Dur-
ing shipping samples are likely to be exposed to a broad range of sea-
sonally and geographically different temperatures. To investigate the
impact of various temperatures a study was performed in which the
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ﬁrmed the impact of constant, higher temperatures on maternal cir-
culating DNA concentrations. Temperature cycling between 6 °C and
37 °C also had an impact on total plasma DNA concentration and
fetal fraction. However, with the experimental set-up shown here,
the effects of cycling and increased temperature cannot be distin-
guished (Supplemental Data Fig. 6). Most carriers offer a limited
form of temperature control during shipment of clinical samples.
Based on our data, reported herein, a shipping container that provides
some insulation to prevent exposure to temperatures >23 °C for
prolonged periods of time is recommended for the transport of
blood collected into Streck BCTs. Finally, a 3-foot drop of whole
blood samples did not alter the circulating DNA concentration.
An interesting observation in this study is the stability of the re-
sults for fetal DNA contributions in the maternal plasma. Similar
levels of fetal DNA were found in all experimental conditions in this
study. The only increase of fetal DNA copies was observed after
14 days of storage in EDTA Tubes and is likely related to limitations
of the measurement method. In the assay used here, unmethylated
maternal DNA is digested with methylation-sensitive restriction en-
zymes and therefore not available for marker ampliﬁcation [10].
When the amount of maternal DNA vastly exceeds fetal DNA
(>1000 fold) incomplete digestion can lead to an overestimation of
“fetal” DNA.
The need for a cell stabilizing BCT will be dictated by the analytical
needs of the application. Qualitative applications, such as prenatal
fetal RHD genotyping, are unlikely to require extended stabilization.
Ampliﬁcation of the RHD locus is speciﬁc and maternal DNA back-
ground in a phenotypically RHD negative mother is unlikely to inter-
fere. In contrast, applications that require a quantitative assessment
of fetal DNA, such as aneuploidy detection, are critically dependent
on a low maternal background. In those applications, a BCT that pre-
vents further maternal cell degradation can eliminate the need for a
complex network of plasma processing sites across the country. As a
result a broad adaptation of otherwise cost prohibitive collection
methods can be enabled.Conclusions
In summary, the results of the evaluation of Streck Blood Collection
Tubes demonstrate that these tubes provide an effective alternative to
blood collection in EDTA Tubes. Streck BCTs enable ambient shipment
to a processing site up to 7 days after blood collection. Therefore these
tubes and validated protocols for their use and handling can enableimplementation of complex molecular testing of ccffDNA and thus
increase patient access to safer non-invasive prenatal testing (NIPT)
methods.
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